

An Integrated Solution for Calculating Results from Tests for Content Uniformity of Dosage Units According to the United States and European Pharmacopeia

Barbara van Cann, Andreas Brunner, Fraser McLeod, Dionex Benelux B.V., Amsterdam, The Netherlands Email: barbara.vancann@dionex.com

INTRODUCTION

In January 2007 the United States Pharmacopeia issued a revision of general chapter <905> that provides details on how to perform uniformity of dosage units experiments.¹ This revision covers procedures for running experiments and for assessing the data. In particular, the revised procedures for assessing the data are more complex. The revised procedure of content uniformity testing for common dosage forms in USP is almost identical to the procedure in the European Pharmacopeia,² but the USP has different requirements for special dosage forms, such as suppositories, transdermal patches, and premetered inhalants.

To ensure the consistency of dosage units, each unit in a batch should have an active substance content within a narrow range of the amount claimed on the label. The content uniformity test is often performed with HPLC. In many labs the chromatographic results are frequently copied into spreadsheets in order to perform the calculations. This process can be time consuming and transcription errors are a common problem.

> Now sold under the Thermo Scientific brand

> > IENTIFIC

In addition, data from two different experiments must often be compared, as the content uniformity test procedure can involve two different experimental stages. For example, if the first 10 units tested do not fulfill the requirements, 20 additional units must be tested and the total of 30 units must be evaluated. Every stage has its own specific pass/fail criteria.

Three different cases for different dosage forms and pharmacopeias, respectively, must be distinguished (Table 1).

	Table 1	. Acceptance Criteria	
Stage	EP and USP common dosage forms ¹	USP suppositories	USP transdermal sys- tems and inhalations packaged in premetered dosage units
1 (n=10)	Acceptance value ≤ maximum allowed acceptance value L1 (L1 is 15.0 by default.)	No unit outside $85.0-115.0\%$ of the label claim ² and RSD $\leq 6.0\%$	No unit outside 75.0–125.0% of the label claim, ² not more than one unit outside 85.0–115.0% of the label claim ² and RSD $\leq 6.0\%$
2 (n=30)	Final acceptance value \leq L1 and no individual content of any dosage is less than (1-0.01*L2)*M nor more than (1+0.01*L2)*M (L2 is the maximum allowed range for deviation of each dosage unit from the refer- ence value and is 25.0 by default.)	No unit outside 75.0–125.0% of the label claim, ² not more than 1 of 30 units outside 85.0-115.0% of the label claim ² and RSD of the 30 units \leq 7.8%	No unit outside 75.0–125.0% of the label claim, ² not more than 3 of 30 units outside 85.0-115.0% of the label claim ² and RSD of the 30 units ≤7.8%

¹Common dosage forms include: uncoated, coated, or molded tablets; capsules; oral solutions in unit-dose containers; suspensions, emulsions, or gels in single-unit containers (that are intended for systemic administration only); and solids (including sterile solids) in single-unit containers.

²Dependent on the average of the limits specified in the potency definition in the individual monograph and mean value of the results, "label claim" is replaced by "label claim multiplied by the average of the limits specified in the potency definition in the individual monograph divided by 100" or by "label claim multiplied by the average value of the units tested (expressed as a percent of label claim) divided by 100".

The Chromeleon[®] Chromatography Management Software (CMS) incorporates advanced features that allow easy calculation of all the content uniformity test results. In addition, the built-in query function allows the creation of a content uniformity report that summarizes the results of two different content uniformity experiments in a single document.

This new content uniformity functionality will speed up the calculation and reporting process, reduce user errors, and provide a convenient method for reporting content uniformity data quickly.

DATA IDENTIFICATION

When performing content uniformity experiments, large amounts of chromatographic data are created, especially when two stages are executed. Workflow is often easier if samples from more than one content uniformity experiment are included in one sequence. If a drug fails the Stage 1 test, the Stage 2 samples may be run in a separate sequence, yet still have to be evaluated with the results from the first stage. Therefore it is very important to identify uniquely the data from different experiments, to facilitate searching and reporting.

All this is achieved through the use of the "User-Defined-Column" function that is available in Chromeleon. For the content uniformity test, a set of user defined columns is created in the sequence (Figure 1). The User Defined Columns (UDC) "CUT_No" and "Test_Stage" are used to identify the required data.

General Access Control Statisti Column	Properties:	(and the second s		
CUT_No Dosage_Form	Nane	Test_Stage		
Phamacopoeia Pioduct, Batch, Number	Value type:	Enumeration		
Test, Slage Oten user-defined columno	Dimension or convert	1		
	F Colympany of			
	Delault terry	n=10		
	Enumenton Imme			
import Columna.	Dekte	Modky		
	OK Cancel	Arch Help		

	X Ra 101 M2 5 5 + 10	1.0.1	\$5.CR.0		回時) 回線	10.00.00.90	s turner lo	0.080/47.080		
is and	Nene / Tite	14	advaire	Lent Lipolete	Operator	5	128			
II Content_Deficienty II Templates	Anney, 1 art Anney art V POM_Cage Solder_C	10	6,8	07.04 3000 12:03:06 25:02.2000 12:46:05 12:05:2007 14:33:15	Sfrange Bange Ovoteleon		21 HB 2 HB 2 HB			
Columnation Columnation	No Varie	10.0	Mi Wines	Course For	m Westard Pater	Station Test	Dage Augiliant	e ED Traini	Pee	Ē
Constant of the second	1 📕 125kg Telety Bells #1234	96 800	102	Coremon Do	#125458	1=10	1	Untrapade	BC5	
	3 🛔 135kg Telets Detch #1304	103 80	USP.	Common Do	#123455	m+10	2	Uninown	BC6	
	125kg Tweete Betch #1234	56 1001	USP	Common Die	#123458	ter10		Unincest	807	
	4 👗 125up Teleta Besch #1254	16 101	105P	Common Do.	#125458	(inter-		Uninterest	808	
	👘 👼 125µg Taoleta (heish #1204	103 401	U.P	Common Do	#125490	m=10		Litensee	BC8	
	1 Stag Taskets Butch #1204	101 801	109	Common De	#123418	0+10		13mmower	8010	
	1 4 125µg Tableta Balch #1334	96 801	1.00	Contention Dis-	#123406	n+10	2	Unimpeen	8011	
	👔 🖉 125pg Talakta Balsta #1254	16 801	1.62	Common Dis	#123458	ri=10		Destowe	8013	
	🔋 🛔 125ug Takata Belch #1234	56 601	192	Common Do	#125485	n+10		Uninpen	8013	
	10 🚪 125pg Talanto (Natch #1254	101 88	USP.	Contempor Dia	#125408	dw1D	10	(animowe)	8A13	
	1+1			in the second second						

Figure 1. User Defined Columns for identification of required data.

The column "CUT_No" displays a user-defined identification of the content uniformity test experiment and offers the user an input field without limitations, allowing the use of internal numbers or codes. The column "Test_Stage" offers the user a drop down list to indicate which stage of the content uniformity experiment is performed with this sample. Available options are stage n = 10 and stage n = 30.

DATA ENTRY FOR CALCULATIONS AND PLOTTING

To be able to calculate all content uniformity results and to create content uniformity plots, additional information is required (Table 2).

1	Gable 2. Additional Information Required	
Field	Description	Location
Pharmacopeia	Choice between EP and USP	Sequence
Dosage_Form	Groups as defined in the USP	Sequence
Product_Batch_Number	Name for the tested batch	Sequence
CUT_No	Number of the experiment	Sequence
Test_Stage	n=10 or n=30	Sequence
L1	Maximum allowed acceptance value	Quantification Method
L2	Maximum allowed range for deviation of each dosage unit tested from the Reference value	Quantification Method
Correction_Factor	Correction factor if analytical methods for assay and content uniformity testing are different	Quantification Method
Target_Content	Target content per dosage unit at time of manufacture expressed as a percentage of the label claim	Quantification Method
dp_Target_Content	Number of decimal points for target content	Quantification Method
Report_Peak	Defines the peak to report	Quantification Method

Analogous to the data identification, User Defined Columns are used to create entry fields for the additional information necessary. If the information is sample specific, the UDCs are created in the sequence (Figure 1 and Table 2). If the information is peak specific, the UDCs are created in the quantification method (Figure 2 and Table 2).

llo. Peak llame	Ret.Time	Standard	Cal.Type	Peak Type	'L1	'L2	'Correction_Factor	'Target_Content	'dp_Target_Content	'Report_Peak
1 Test Substance	11,767 min	External	LOW	Auto	15.0	25.0	1.050	102.0	1	1st
2 Peak 2	15.000 min	External	LON	Auto	15.0	25.0	1.050	102.0	1	2nd
3 Peak 3	17.000 min	External	LOff	Auto	15.0	25.0	1.050	102.0	1	3rd

Figure 2. User Defined Columns in the quantification method.

One report is used for content uniformity testing according to the European Pharmacopeia and "common" dosage forms according to the United States Pharmacopeia. The second report is used for Suppositories, Transdermal Systems, and Inhalations Packaged in Premetered Dosage Units tested according to the USP. The content of the UDCs "Dosage_Form" and "Pharmacopeia" determines which report to use. While one report is valid, the other one automatically gets invalid and a warning that this sheet is invalid is displayed. Three analogous reports are available in parallel for reporting up to three different active substances in multi-drug products.

RESULT CALCULATION

Chromeleon provides all standard chromatographic calculation tools, such as amount, statistical calculations (e.g. average, standard deviation and relative standard deviation), and advanced spreadsheet formulas. These calculations can be applied to any user-defined data set.

Case 1: United States Pharmacopeia for common dosage forms and European Pharmacopeia

Stage 1 of the content uniformity test starts with 10 dosage units. An acceptance value is calculated from the test results, which is compared to the maximum allowed acceptance value L1. If the calculated acceptance value is not greater than L1, the test has passed as shown in Figure 3. In this example, the methods for assay and content uniformity are different and the determined correction factor is outside the range of 0.97–1.03. Therefore, the results for the active substance are multiplied by the correction factor in order to calculate the corrected amount.

		B B P P P H H I	▶ 白色の 図目目	医 四 多 目 章 田 田	1 田 田	1
_	A	B	c	D	E	
1	Uniformity of	Dosage Units R	eport			
2						t
3	General					t
4	Product Batch Number	#123456	Target Content 7	102.0		ł
5	Peak Name	Test Substance	Correction Factor	1.050		t
6	Channel	UV VIS 1	Max Acceptance Value L1	15.0		t
7	Dosage Form	Common Dosage Forms	Lower Amount Limit	Not needed if n=10i		t
8	Pharmecopeia	USP	Upper Amount Limit	Not needed if n=10!		Ē
9						
10	Results		n = 10			
11	Mean		105.4			t
12	Standard Deviation s		2.8			
13	Reference Value M		102.0			
14	Acceptance Value AV		10.0			
15	Test Result		Test passed			
16	110203		100012000			
17	Replicate ID	Name	Amount	Corrected Amount	Evaluation	Į.
18	and the second	100000	100.9530	[%]		Ľ
19						ľ
20			UV_VIS_1			F
21	1	125ug Tablets Batch #123456	99.0	103.9	n.a.	ľ
22	2	125µg Tablets Batch #123456	119.8	105.0	6.8	ľ
23	3	125ug Tablets Batch #123456	100.4	105.4	n.a.	ĩ
24	4	125µg Tablets Batch #123456	98.5	103.4	n.a.	Ľ
25	5	125µg Tablets Batch #123456	99.8	110.0	n a	ľ
26	6	125µg Tablets Batch #123456	103.1	108.3	n.a.	ľ
27	7	125µg Tablets Batch #123456	103.4	108.6	n.a.	ľ
28	8	125ug Tablets Batch #123456	96.9	101.8	n.a.	ľ
29	9	125µg Tablets Batch #123456	97.5	102.4	6.8.	ľ
30	10	125ug Tablets Batch #123456	99.9	104.9	n a	r

Figure 3. Content uniformity report for case 1 and n = 10.

The table in Figure 4 shows a failed n = 10 case (acceptance value = 21.7). The test result displays the message "Test additional 20 units!" indicating the requirement to continue the content uniformity test with Stage 2. After the additional units have been analyzed and the results are available, the acceptance value is calculated again. It must not be greater than L1. Additionally, no individual unit may lie outside the interval between lower and upper amount limit. These limits depend on the Target Content and the Mean Value and are calculated automatically. Each result is evaluated as "Pass" or "Fail" (Figure 4).

	Edit Vew Format Worksp					
) 2		10 10 1 0 0 1 H H	● 非选择 La 翻翻 C			1.1.1.1.1
-	A	B		0	E	F
1	Uniformity of	Dosage Units R	eport			1
2						
3	General					
4	Product Batch Number	#123456	Target Content T	102.0		
5	Peak Name	Test Substance	Correction Factor	1.050		
6	Channel	UV_VIS_1	Max Acceptance Value L1	15.0		
7	Dosage Form	Common Dosage Forms	Lower Amount Limit	77.0		
8	Pharmacopeia	USP	Upper Amount Limit	127.0		
9						
10	Results		m = 10	n = 30		
11	Mean		106.9	106.1		
12	Standard Deviation a		7.0	4.7		
13	Reference Value M		102.0	102.0		
14	Acceptance Value AV		21.7	13.6		
15	Test Result		Test 20 additional units!	Test passed!		
16						
17	Replicate ID	Name	Amount	Connected Amount	Evaluation	
18				[%]		
19			Concernance of the Concernance o			
20			UV_VIS_1		1000	
21	1	125µg Tablets Batch #123466	99.0	103.9	Pass	
22	2	125ug Tablets Batch #123455	119.8	125.8	Pass	
23	3	125µg Tablets Batch #123455	100.4	105.4	Pass	
24	4	125µg Tablets Batch #123456	98.5	103.4	Pass	
25	6	125ug Tablets Batch #123456	99.8	104.8	Pass	
26	6	125ug Tablets Batch #123455	103.1	108.3	Pass	
27	7	125ug Tablets Batch #123456	103.4	108.6	Pass	
28	8	125ug Tablets Batch #123455	95.9	101.8	Pass	
29	9	125ug Tablets Batch #123458	97.5	102.4	Pass	
30	10	125ug Tablets Batch #123456	99.9	104.9	Pass	
31	11	125µg Tablets Batch #123456	99.8	104.7	Pass	
32	12	125ug Tablets Batch #123456	103.6	108.8		
33	13	125ug Tablets Batch #123456	98.7	103.6		
34	14	125ug Tablets Batch #123456	100.6	105.6		
35	15	125ug Tablets Batch #123456	101.3	105.4	Pass	

Figure 4. Content uniformity report for case 1 and n = 30.




Figure 5. Individual results of content uniformity plot and final test results.

Figure 5 shows the graphical representation of the results. The lower and upper amount limits are indicated as horizontal lines in the graph.

Case 2: USP and Suppositories, Transdermal Systems, and Inhalations Packaged in Premetered Dosage Units

For Suppositories, Transdermal Systems (TDS), and Inhalations Packaged in Premetered Dosage Units, the United States Pharmacopeia has defined individual, although similar, criteria. The criteria for suppositories are stricter than for TDS and Inhalations.

No acceptance values are calculated here. To pass the test, each single result must lie within a certain interval and the RSD must not exceed 6.0 (for n = 10) and 7.8% (for n = 30), respectively. Figure 6 shows how the results of a suppository test are presented in the Chromeleon report. Because one unit was outside the Stage 1 test limits (strict limits, dashed purple lines) and the RSD was above 6.0%, the Stage 2 test had to be performed. All results were within the Stage 2 test limits (wide limits, solid blue lines) and the RSD was well below the Stage 2 limit of 7.8%.




Figure 6. Final test results and plot for Special Dosage Forms.

REPORTING THE SECOND STAGE

If the test of 10 units fails, another 20 units must be tested. For evaluation, the results from the previous test also must be included. Most often these test results are distributed across different sequences.

In order to bring all the data together it is necessary to run a Chromeleon query. For content uniformity testing, the query required is simple and can be easily created using the Query Wizard available in Chromeleon. The necessary information for the query to locate all samples for the content uniformity experiment is the content uniformity test number (CUT_No, in this example 001) and the test stage information (Figure 7). Once a query is run, a virtual sequence (Figure 8) containing all the relevant data is created.

Data Field	Operator	Value:	
"Sample CUT_No	<u>.</u> .	• 001	AND .
Dala Field	Operator.	Value:	
"Sample Test_Stage	× •	n-10	• OR •
Data Field	Operator	Value:	
"Sample Test_Stage	<u>.</u> .	■ n~30	. H .
Data Field	Operator	Value	100
Jala Piekz	Uperator	y okue	+

Figure 7. Required steps of the Query wizard in order to collate the required sample data.

	X ID	E N F P P F H H		100.00	1201	關口除	(1) 98 (1)	101 301 301	THE SHE IS	1. 15	90	
	Seque		/ Htt	Title			Testate	Last Updat	e) - 2	Operator		
Undomity lates		ntert_Uniformit/CUT_n10.5E0 ntert_Uniformit/CUT_n20.5E0	10				HPLC_4 HPLC_4	04.04,2000		Trivenze Trivenze		
	10.00	ne la	estate D	[stur)	No Test Stay	Trucket Bat	In Number	Pharmacopoleia	Cosage Fr	-	Type	F
2	1 1	125au Tableto Batch #123456 1		001	8+10	#123455		154	Supporterior		Uninown	-
()	2 4	125pg Tablets Betch #123456 2		001	e+10	#123455		150	Suppostorie		Uningwin	
	2 8	125up Tableta Betah #123456 3		001	m=10	#123455		rtip	Suppostorie		Unknown	
	4 4	125pp Tableto Detch #123456 4		001	m+10	#123455		159	(hancostorie		Uninewn	
	5	125µg Tablets Detch #123456 S		001	m+10	#123455		150	Suppostorie		Unknown	
	. 1	125µp Teleto Brinn #123456 6		001	e=10	#123455	1	150	Secondarie		Uninown	
	7	125µg Tablets Detch #125456 7		001	m+10	#123455		KSP .	Supporterie		Unincien	
	= 8	125pg Teletra Botuh #123456 @		001	m=10	#123455		1529	Suppositorie	÷.	Uninown	
	- 5 4	125µg Tablets Belch #123458 %		001	8+10	#123455		15P	Supporterie		Uningwn	
	110	125µg Tableto Belon #123456 10	p -	001	dw10	#123455	1	152	Suppositorie		Unknown	
	111	125pg Teller's Below #123456 11	6	001	e=30	#123458	4	102	Depostore		Unknown	
	32	125ap Tableta Botch #123456 13	2	001	n=00	#123455		KSP .	Suppostore		Uninown	
	13	125pg Tebets Detch #123456 13	3	001	m-30	#123458		15 2	Suppostorie	÷	Uninown	
	14	125µp Teltiete Betch #123456 14	6	001	.ex30	#123458	4	/DP	Suppositorie	19	Uninown	
	15	125pp Tableta Belon #123456 11	5	001	ew30	#123456		t\$P	Suppostorie		Unknown	
	16	125µg Tablets Betch #123456 14	8	001	#++30	#123455	1	108	Supporterie		Uningwith	
	17	125up Tableto Betch #123456 12	1	001	ew30	#123456		15P	Suppostorie		Uningwis	
	10	125µg Tablets Detch #123456 1		001	#+-30	#123455	6	108	Secondarie	16	Uninown	
	15	125µg Twints Buich #123456 11	P	001	e#30	#123456		KP	Suppostore		Uninown	
	20	125µg Teleta Detri #123456 20	£.	001	#=30	#123455	1	158	Suppostorie		Uninown	
	25		6	001	##30	#123455	1	159	Supporterie	16	Uningwith	
	22	125µg Tablets Betch #123456 22	8	001	m+30	#123455		t\$P	Suppostorie		Uninown	
	23		1	001	e=30	#123458		159	Suppositore		Uninown	
	24	125µg Tablets Betch #123456 (2)	£	001	m+30	#123455	4	15P	Supporterie	10	Unknown	
	25	125µg Talanta Britch #123456 25	5	001	n=30	#123455		rsp	Suppositorie		Unknown	
	26	125µg Teleta Beluh #123456 28	6	001	#=30	#123455	5	15P	Suppostorie		Uninown	. 1
	27		t)	001	m+30	#123455		X\$P	Suppostorie		Uhinown	
	28			001	6#30	#123455		155	Seportorie		Untercon	1.1
	1		· .		**							M

Figure 8. Query result.

This data can then be reported in order to create the final content uniformity report. Chromeleon also supports the creation of an electronic version of the report using the Adobe portable document file format (.pdf). This makes it very easy to distribute the report for review or for inclusion into a data submission package.

Thermond State							
	Content Uniformity Report Samples for Content Uniformity Test N		\$123406		The Defense	201	10
Rente trees	Postum C. Arran harm	Tax Item	International Destates	Departure Topolo		nuclater linear	and the second se
000							
	COLUMN TRACTORY	- 101	Const. Collinso	68.40	10.171	- ME 1	
	2 Sha Mealine Pares		SKING-JOBION	800	1.4.4		- 14
and a second sec	 Use Set Set 2011 Use Set 80, 804, 905 	10	Octor United	- 22	100.01	14	2.8
Etter the base	E Dia familian ruinte		Samet Antonia	60 ct	10.70	0.4	14
5 5 5 5	E 125/a Televisite/A PC2988		Outlief, Unbirds	D.F. 41	305.305	**	
and the second	Columnation of the second s		Contract Lindscole	647 etc.	- 58.MT 	1.6	1.4
in the second state of the	6 Charleton Lost # 2001		Carriers coefficients	- 62CH	6.58	10.00	+ *
	St. Sha Seen Sent # Stell.		Senter_University	601.21 007.21 201.52	8.301	2.6	
	 Chan Tuber, Book # 22-691 Chan Tuber, Santa # 22-691 	-+-12	Content Uniformity Content Uniformity	20.7 Max	10.101	1.4	2.4
	Coll Colling Trailings, Survey, Michael M.	10.00	Cartiert Linducties		19.511	2.4	8.8
	15, 12ba (Anh Anh 6 2240)	22	Garnet Johnste	形が	18.00		
	15 Chia Taken, June P. Dollar 16 Chia Taken, Benn P. 2048.	+10	Center, Microly Center, University	0.1 ×0.1 10.1 ×0.1	10.201	**	14
	11 Star Area loca # Sold	1415	Context, Uniternals	1	100 (h) 		1.4
and the second s	 Chan Talvin, Rent P (2008) Chan Talvin, Rent P (2008) 		Sacher Linderste Sacher Linderste	3728	16.6	- 14	
	21 Using Calance Street # 2014		Senar Antonia	3.3		24	1.4
	24 Obja Tatesh Book # Updat		Canter Lottents	247.52			2.4
-	22 Charleton Rock # 2048	10	Carter Johnson		10-11-1 M-14	14	
2"2" H L.	 Dia Mais Rest #20411 		 Content Application 	and her	126,7541	- 10.4c	
5 11	2 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	- 138	CATTART, UNITED A	100	10.44	14	- 58
allen insta	1 Use Am hat First	32	Surrer Culture A	241_258	100.001		1.4
h manufacture	2 Star Sector 2000		Server, Leftersky		18.17	1.0.0	2.0
And the second s	20 Sha Am Son Cold		- Sector Litelatols		MIG		
and the second s	TO 125 A TAKING SHOP AND A TAKING A TAK	1410		0AT N2	1 - 10 10 - 1	2.4	1.4

Figure 9. Electronic content uniformity report.

CONCLUSION

The Chromeleon Chromatography Management Software offers a fast and simple way of producing content uniformity reports in accordance with the EP and USP rules. This provides the following benefits to laboratories:

- Increased laboratory productivity—users can spend more time running experiments and less time performing manual data transcription and calculations.
- Increased reliability of results—transcription errors and errors caused by manual calculations are eliminated.

- Faster creation of content uniformity reports—the built-in Chromeleon query function and flexible reporting tool enables content uniformity reports to be created through two mouse clicks.
- Improved distribution of content uniformity reports—the easy creation of electronic content uniformity reports using Chromeleon means that reports can be easily distributed for review.

REFERENCES

- 1. United States Pharmacopeia USP30-NF25, Chapter 905, Uniformity of Dosage Units, 2008.
- 2. European Pharmacopeia 6.1, Chapter 2.9.40 Uniformity of Dosage Units, 2008.

Chromeleon is a registered trademark of Dionex Corporation.

Passion. Power. Productivity.

North America

Dionex Corporation 1228 Titan Way

P.O. Box 3603

Sunnyvale, CA

(408) 737-0700

94088-3603

l

U.S. (847) 295-7500 Canada (905) 844-9650 **South America** Brazil (55) 11 3731 5140

Europe

Austria (43) 1 616 51 25 Benelux (31) 20 683 9768; (32) 3 353 4294 Denmark (45) 36 36 90 90 France (33) 1 39 30 01 10 Germany (49) 6126 991 0 Ireland (353) 1 644 0064 Italy (39) 02 51 62 1267 Switzerland (41) 62 205 9966 United Kingdom (44) 1276 691722

Asia Pacific

Australia (61) 2 9420 5233 China (852) 2428 3282 India (91) 22 2764 2735 Japan (81) 6 6885 1213 Korea (82) 2 2653 2580 Singapore (65) 6289 1190 Taiwan (886) 2 8751 6655



www.dionex.com

©2008 Dionex Corporation

DIONE